Articles From: Xcite Energy Limited ("Xcite Energy" or the "Company") Memorandum of Understanding With AIBEL AS to Xerox Declares Dividend on Common and Preferred Stock


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1128836&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited ("Xcite Energy" or the "Company") Memorandum of Understanding With AIBEL AS investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1129816&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited ("Xcite Energy" or the "Company"): Director Share Purchases investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1138635&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited Announces Award of Options investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1127963&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited Announces Exercise of Share Options investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1137767&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited Announces Results for 3 and 6 Month Periods Ended 30 June 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1127959&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited Announces Settlement of Senior Secured Bond and Admission of New Shares investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1143539&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited Collaboration Agreement With Statoil and EnQuest investment picks
Conference call today at 4:30 p.m. EDT MONROVIA, Calif.
Sign-up for Xencor Reports Second Quarter 2014 Financial Results investment picks
http://media.marketwire.com/attachments/201408/78171_xenetic.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1136809&ProfileId=051205&sourceType=1 LEXINGTON, MA --
Sign-up for Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R) investment picks
LEXINGTON, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO) , a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced results from its ongoing data analysis of the first cohort of its Phase 2, sequential multiple dose study evaluating the safety and efficacy of ErepoXen ® , subcutaneously administered polysialylated erythropoietin (PSA-EPO), for the treatment of anemia in Chronic Kidney Disease (CKD) patients who are neither on dialysis nor receiving erythropoiesis stimulating agents.
Sign-up for Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R) investment picks
RICHMOND, Va., July 1, 2014 (GLOBE NEWSWIRE) -- Xenith Bankshares, Inc. (Nasdaq:XBKS) , parent company of Xenith Bank, today announced the completion of its acquisition of Colonial Virginia Bank ("CVB"), whereby CVB was merged with and into Xenith Bank.
Sign-up for Xenith Bankshares, Inc. Announces Completion of Colonial Virginia Bank Acquisition investment picks
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that they have entered into an agreement to conduct a clinical trial of HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT.
Sign-up for XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder investment picks
XenoPort, Inc. (Nasdaq: XNPT) announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate.
Sign-up for XenoPort Announces Initiation of a Phase 2 Clinical Trial of XP23829 in Patients With Psoriasis investment picks
XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the second quarter and six months ended June 30, 2014.
Sign-up for XenoPort Reports Second Quarter Financial Results investment picks
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference.
Sign-up for XenoPort to Present at the Morgan Stanley Global Healthcare Conference investment picks
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on XP23829, an investigational prodrug of monomethyl fumarate (MMF), at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Sign-up for XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston investment picks
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its second quarter financial results on August 6, 2014 at approximately 4:30 p.m. Eastern Time.
Sign-up for XenoPort to Release Second Quarter Financial Results on August 6, 2014 investment picks
YOUNGSVILLE, N.C., July 31, 2014 (GLOBE NEWSWIRE) -- Xerium Technologies, Inc. (NYSE:XRM) , a leading global provider of industrial consumable products and services, today announced that it has initiated closure proceedings with the representative union officials at its PMC facility in João Pessoa, Brazil.
Sign-up for Xerium Announces Planned Closure of Brazilian PMC Facility investment picks
YOUNGSVILLE, N.C., Sept.
Sign-up for Xerium Announcing Long-Term Growth and Debt Pay Down Plans investment picks
YOUNGSVILLE, N.C., Aug.
Sign-up for Xerium Introduces EnerVent Roll Cover Venting Technology for Tissue Machines investment picks
YOUNGSVILLE, N.C., July 16, 2014 (GLOBE NEWSWIRE) -- Xerium Technologies, Inc. (NYSE:XRM) , a leading global provider of industrial consumable products and services, today issued an investor update.
Sign-up for Xerium Investor Update investment picks
Adjusted EBITDA improves over 2013 Q2 and Q1 2014 No change to full year 2014 guidance range of $116 to $120 million Adjusted EBITDA YOUNGSVILLE, N.C., Aug.
Sign-up for Xerium Reports Second Quarter Results investment picks
YOUNGSVILLE, N.C., Aug.
Sign-up for Xerium Takes Advantage of Brazilian Tax Amnesty Opportunity investment picks
Xerox (NYSE:XRX) is teaming up with MoneyGram, a leading money transfer and payment services company, to assist people in transmitting child support payments to state agencies and custodial parents.
Sign-up for Xerox and MoneyGram to Transform Child Support Payments investment picks
Xerox's (NYSE:XRX) board of directors today declared a quarterly cash dividend of 6.25 cents per share on Xerox common stock.
Sign-up for Xerox Declares Dividend on Common and Preferred Stock investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Xcite Energy Limited ("Xcite Energy" or the "Company") Memorandum of Understanding With AIBEL AS to Xerox Declares Dividend on Common and Preferred Stock
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices